SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Billie Holiday

PatientBillie Holiday
Date of birth1993-04-07
IdentifiersMRN HR-ML010-SYN; SSN (made up) 000-10-4472
Document date2026-05-26
AuthorConstance Mayfield, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Five-week recovery review and second hepatitis B vaccine. [S]

History of Present Illness

Ms. Holiday returns five weeks after starting buprenorphine, after a three-week tour. She has taken 16 mg every morning without a gap and has used no heroin or other opioids. Cravings are now brief and come mostly late at night after a show; she calls her peer recovery coach when they do. She takes acamprosate most days but sometimes forgets the midday dose. She has cut down to two or three drinks on performance nights. She spoke with her counselor by phone each week while away. Her mood is a little better. She kept the naloxone in her bag and has not needed it. [S]

ElementDetail
Buprenorphine16 mg daily, no gaps
Opioid useNone
CravingsBrief, late at night; she calls her peer coach
AlcoholTwo or three drinks on performance nights
AcamprosateMost days; misses some midday doses

Review of Systems

SystemResultFinding
GastrointestinalNegativeConstipation settled; no nausea
PsychiatricPositiveMood somewhat low at times; no thoughts of suicide or self-harm
NeurologicalNegativeNo tremor or unsteadiness

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Buprenorphine 8 mg and naloxone 2 mg sublingual film: half a film (4 mg) on day 1, then one film (8 mg) under the tongue dailyOne film under the tongue daily after a 4 mg first doseSublingual route2026-04-20 to 2026-04-27completedS
Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once dailyTwo films under the tongue once dailySublingual route2026-04-27activeS
Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils; call 911One spray (4 mg) in one nostril for suspected overdose; repeat every 2 to 3 minutes if there is no responseNasal route2026-04-20activeS
Acamprosate 333 mg delayed-release oral tablet, two tablets (666 mg) by mouth three times dailyTwo tablets by mouth three times dailyOral route2026-04-27activeS
Thiamine 100 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-04-20 to 2026-10-19completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-05-26Body height165cmS
2026-05-26Body weight68.6kgS
2026-05-26Body mass index (BMI) [Ratio]25.2kg/m2S
2026-05-26Systolic blood pressure118mm[Hg]S
2026-05-26Diastolic blood pressure76mm[Hg]S
2026-05-26Heart rate74/minS
2026-05-26Respiratory rate14/minS
2026-05-26Body temperature36.6CelS
2026-05-26Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-05-26Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma38U/L10-40 U/LNormalS
2026-05-26Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma30U/L7-56 U/LNormalS
2026-05-26Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma52U/L5-40 U/LHighS
2026-05-26Phosphatidylethanol [Mass/volume] in Blood96ng/mLBelow 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinkingHighS
2026-05-26Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S

Physical Exam

Vital signs recorded on 2026-05-26; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 118/76, pulse 74
AbdomenSoft and non-tender; no liver enlargement
PsychiatricEngaged; no signs of intoxication or withdrawal

Problems

ProblemClinical statusVerificationCodeProvenance
Opioid use disorder (heroin), severe; in early remission in a controlled environment at intake, five weeks after release from custody; on buprenorphine; synthetic modern episode linked to her documented heroin useactiveconfirmed F11.20S — Synthetic modern coding of the documented heroin addiction; language is person-first, and the code does not change with a return to use.
Alcohol use disorder, moderate; synthetic modern episode linked to her documented heavier drinking after her mother's deathactiveconfirmed F10.20S — Synthetic modern coding of the documented drinking; the liver disease reported in her last year is not coded, because it was documented long after the episode.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Medication safetyBuprenorphine dose, adherence, cravings, withdrawal, and side effectsEvery visitCompleted today16 mg daily without gaps; brief cravings; no sedation
Self-managementVisit frequencyEvery 1 to 2 weeks in the first month after starting, then every 2 to 4 weeks until stableDeferredFour weeks since the one-week visit, longer than the one to two weeks advised in the first month, because she was on tour; the planned call-in visit at two weeks did not happen. Weekly counseling calls continued, and no harm resulted. Corrective action: video check-ins every two weeks between visits while touring
LaboratoryUrine drug testing, including fentanyl, explained as part of care rather than as a test of trustAt the start, then about monthly early in treatment and as neededCompleted todayBuprenorphine and norbuprenorphine only
Medication safetyPrescription drug monitoring program checkBefore each buprenorphine prescriptionCompleted todayNo other prescriptions
Medication safetyNaloxone at home and in her bag, and a trained companionAt the start; check and replace at each visitCompleted todayIn her bag and at home; not used
Self-managementOverdose prevention: never using alone and fentanyl test stripsEvery visitCompleted todayReviewed
Self-managementCounseling and peer recovery supportOffered to everyone; not a condition of medicationCompleted todayWeekly counseling by phone on tour; peer coach by phone
SurveyDrinking and PEthPEth at intake and at each check while drinking continues; AUDIT-C yearlyCompleted todayPEth 96 ng/mL, from 312; two or three drinks on performance nights
Medication safetyAcamprosate adherence and kidney functionKidney function before starting; adherence every visitCompleted todayMissing some midday doses; reminder set
Medication safetyThiamineWhile drinking heavilyCompleted todayTaking thiamine daily
LaboratoryLiver tests (AST, ALT, GGT, albumin, bilirubin)At intake, then every 1 to 3 months while drinking is heavy, and yearlyCompleted todayAST 38, ALT 30, GGT 52 U/L, improving
LaboratoryFIB-4 fibrosis scoreAt intake; repeat in 6 to 12 months with ongoing drinking, and every 1 to 2 yearsUp to date1.18 at intake; repeat at six months
ImagingVibration-controlled transient elastographyIf FIB-4 is 1.3 or higherNot indicatedFIB-4 below 1.3
Self-managementHepatitis A and B vaccinesHepatitis B two doses 4 weeks apart; hepatitis A two doses 6 months apartCompleted todayHepatitis B dose 2 given today; hepatitis A dose 2 at six months
SurveyDepression screen (PHQ-9)At intake and at each recovery visit while symptoms are presentCompleted todayPHQ-9 7, item 9 scored 0
SurveySuicide and overdose risk review, safety plan, and the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide or self-harm; safety plan and the 988 Suicide & Crisis Lifeline in her phone

Goal progress:

Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2 [S]

Guideline basis: The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Treatment Options for Substance Use Disorder (medications for opioid and alcohol use disorders) (2026); VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021); Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019); AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis (2025); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); Adult Immunization Schedule by Medical Condition and Other Indication (2026); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Video check-ins every two weeks while touring. Three-month visit with PEth, liver tests, and the PHQ-9. Next scheduled visit 2026-07-20: three-month review after a return to opioid use: adjusting the recovery plan. [S]